ADVERTISEMENT
Big Pharma’s First Female CEO Disrupts Glaxo From Within
Emma Walmsley has replaced about 100 of her top 125 managers since she took over in 2017.
23 Jul 2019, 03:38 PM IST
(Bloomberg Businessweek) -- When GlaxoSmithKline Plc bought cancer-treatment maker Tesaro for $5.1 billion last year, skeptics panned the deal, and the stock tumbled. On July 15 a key medicine acquired in the transaction yielded positive results, a small victory in Chief Executive Officer Emma Walmsley’s bid to overhaul the British drugmaker.
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Free
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT